Patent ID: 11939389
Assignee: NOVARTIS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 82:
83. A method of treating a subject having a multiple myeloma, the method comprising administering to the subject an effective amount of autologous T cells comprising a CAR that binds to BCMA, wherein the CAR comprises, from N-terminus to C-terminus:
(a) an HC CDR1 of SEQ ID NO: 86;
(b) an HC CDR2 of SEQ ID NO: 87;
(c) an HC CDR3 of SEQ ID NO: 88;
(d) an LC CDR1 of SEQ ID NO: 95;
(e) an LC CDR2 of SEQ ID NO: 96;
(f) an LC CDR3 of SEQ ID NO: 97;
(g) a CD8 transmembrane domain and hinge of SEQ ID NO: 202;
(h) a functional signaling domain of 4-1BB of SEQ ID NO: 7; and
(i) a functional signaling domain of CD3 zeta of SEQ ID NO: 10.